VivoSeq
Oncology

Anatomic Stage II Breast Cancer AJCC V8

14

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Anatomic Stage II Breast Cancer AJCC v8 is an emerging landscape with 14 programs across 8 companies. The most active players are Avyxa, Bristol-Myers Squibb, Pfizer. 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

27/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3Novartis logo

Novartis

2 programs

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3Teva logo

Teva

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

10 of 15 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody427%Antibody–drug conjugate17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low)
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT07391774·1,978 enrolled
Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT06058377·3,680 enrolled
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 2·NCT04266249·2,175 enrolled
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT05812807·1,295 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)